Ophthalmic therapy developer Elumninex Biosciences has secured a $50 million Series A round of financing co-led by Hillhouse Capital’s VC arm GL Ventures, Shanghai-based biomedical VC firm Lilly Asia Ventures (LAV), and Quan Capital, as per a company statement on Tuesday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
